Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Natalizumab will not be provided to participants by Biogen as a part of this study. Participants will remain on natalizumab therapy as prescribed by their physician.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of RRMS.
Continuous treatment with natalizumab of ≥24 months. In case of a treatment interruption from natalizumab ≥60 days after a total treatment period of ≥24 months, only the treatment prior to the interruption will be analyzed. Any data after this treatment interruption (even if the patient restarts natalizumab) will not be analyzed/collected.
≥1 MRI scan of sufficient quality for reliable measurement.
Baseline MRI scan ≤6 month prior to natalizumab treatment acquired.
≥1 MRI scan of sufficient quality for reliable measurement taken while on natalizumab treatment for ≥6 months.
EDSS ≤ 6.5.
You may not be if
Anti-natalizumab antibody detection.
Prior treatment with alemtuzumab.
Prior treatment with mitoxantrone within 12 months of the first infusion of natalizumab.
